AU Patent

AU2017232080B2 — Metalloenzyme inhibitor compounds

Assigned to Mycovia Pharmaceuticals Inc · Expires 2019-02-14 · 7y expired

What this patent protects

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such 5 metalloenzymes.

USPTO Abstract

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such 5 metalloenzymes.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017232080B2
Jurisdiction
AU
Classification
—
Expires
2019-02-14
Drug substance claim
No
Drug product claim
No
Assignee
Mycovia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.